Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models

• Main Authors: Dr Prof Marc Brisson, PhD, Élodie Bénard, MSc, Mélanie Drolet, PhD, Johannes A Bogaards, PhD, Iacopo Baussano, MD, Simopekka Vänskä, PhD, Mark Jit, PhD, Prof Marie-Claude Boily, PhD, Megan A Smith, MPH, Johannes Berkhof, PhD, Prof Karen Canfell, PhD, Harrell W Chesson, PhD, Emily A Burger, PhD, Yoon H Choi, PhD, Prof Birgitte Freiesleben De Blasio, PhD, Sake J De Vlas, PhD, Giorgio Guzzetta, PhD, Jan A C Hontelez, PhD, Johannes Horn, Dipl Biomath, Martin R Jepsen, PhD, Prof Jane J Kim, PhD, Fulvio Lazzarato, MSc, Suzette M Matthijsse, MSc, Rafael Mikolajczyk, MD, Andrew Pavelyev, PhD, Matthew Pillsbury, PhD, Leigh Anne Shafer, PhD, Stephen P Tully, PhD, Hugo C Turner, PhD, Cara Usher, PhD, Prof Cathal Walsh, PhD
• Format: Article
• Language: English
• Published: Elsevier 2016-11-01
• Series: The Lancet Public Health
• Online Access: http://www.sciencedirect.com/science/article/pii/S2468266716300019

Background: Modelling studies have been widely used to inform human papillomavirus (HPV) vaccination policy decisions; however, many models exist and it is not known whether they produce consistent predictions of population-level effectiveness and herd effects. We did a systematic review and meta-analysis of model predictions of the long-term population-level effectiveness of vaccination against HPV 16, 18, 6, and 11 infection in women and men, to examine the variability in predicted herd effects, incremental benefit of vaccinating boys, and potential for HPV-vaccine-type elimination. Methods: We searched MEDLINE and Embase for transmission-dynamic modelling studies published between Jan 1, 2009, and April 28, 2015, that predicted the population-level impact of vaccination on HPV 6, 11, 16, and 18 infections in high-income countries. We contacted authors to determine whether they were willing to produce new predictions for standardised scenarios. Strategies investigated were girls-only vaccination and girls and boys vaccination at age 12 years. Base-case vaccine characteristics were 100% efficacy and lifetime protection. We did sensitivity analyses by varying vaccination coverage, vaccine efficacy, and duration of protection. For all scenarios we pooled model predictions of relative reductions in HPV prevalence (RRprev) over time after vaccination and summarised results using the median and 10th and 90th percentiles (80% uncertainty intervals [UI]). Findings: 16 of 19 eligible models from ten high-income countries provided predictions. Under base-case assumptions, 40% vaccination coverage and girls-only vaccination, the RRprev of HPV 16 among women and men was 0·53 (80% UI 0·46–0·68) and 0·36 (0·28–0·61), respectively, after 70 years. With 80% girls-only vaccination coverage, the RRprev of HPV 16 among women and men was 0·93 (0·90–1·00) and 0·83 (0·75–1·00), respectively. Vaccinating boys in addition to girls increased the RRprev of HPV 16 among women and men by 0·18 (0·13–0·32) and 0·35 (0·27–0·39) for 40% coverage, and 0·07 (0·00–0·10) and 0·16 (0·01–0·25) for 80% coverage, respectively. The RRprev were greater for HPV 6, 11, and 18 than for HPV 16 for all scenarios investigated. Finally at 80% coverage, most models predicted that girls and boys vaccination would eliminate HPV 6, 11, 16, and 18, with a median RRprev of 1·00 for women and men for all four HPV types. Variability in pooled findings was low, but increased with lower vaccination coverage and shorter vaccine protection (from lifetime to 20 years). Interpretation: Although HPV models differ in structure, data used for calibration, and settings, our population-level predictions were generally concordant and suggest that strong herd effects are expected from vaccinating girls only, even with coverage as low as 20%. Elimination of HPV 16, 18, 6, and 11 is possible if 80% coverage in girls and boys is reached and if high vaccine efficacy is maintained over time. Funding: Canadian Institutes of Health Research.